References
- Lawrence DK, Gill EV. The effects of Δ-9-tetrahydrocannabinol and other cannabinoids on spin-labeled liposomesand their relationship to mechanisms of general anesthesia. Mol. Pharmacol.11, 595–602 (1975).
- Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology47, 345–358 (2004).
- Pertwee R. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol.168, 1–51 (2005).
- Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev.58, 389–462 (2006).
- Bouaboula M, Poinot-Chazel C, Bourrié B et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J.312, 637–641 (1995).
- Rueda D, Galve-Roperh I, Haro A, Guzmán M. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol.58, 814–820 (2000).
- Liu J, Gao B, Mirshahi F et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J.15, 835–840 (2000).
- Gómez del Pulgar T, De Ceballos M, Guzman M, Velasco G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem.39, 36527–36533 (2002).
- Derkinderen P, Toutant M, Burgaya F et al. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science273, 1719–1722 (1996).
- Gómez del Pulgar T, Velasco G, Sánchez C, Haro A, Guzmán M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem. J.363, 183–188 (2002).
- Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol.6, 35–42 (2005).
- Guzmán M. Cannabinoids: potential anticancer agents. Nature Rev.3, 745–755 (2003).
- Kogan NM. Cannabinoids and cancer. Mini Rev. Med. Chem.5, 941–952 (2005).
- Bifulco M, Laezza C, Pisanti S, Gazzerro P. Cannabinoids and cancer: pros and cons of antitumour strategy. Br. J. Pharmacol.148, 123–135 (2006).
- Velasco G, Galve-Roperh I, Sánchez C, Blazquez C, Guzmán M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology47, 315–323 (2004).
- Sathornsumetee S, Reardon D, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer110, 13–24 (2007).
- Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N. Engl. J. Med.353, 811–822 (2005).
- Stupp R, Mason WP, van der Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
- Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet345, 1008–1012 (1995).
- Yamanaka R. Novel immunotherapeutic approaches to glioma. Curr. Opin. Mol. Ther.8, 46–51 (2006).
- Sánchez C, Galve-Roperh I, Canova C, Brachet P, Guzmán M. Δ9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett.436, 6–10 (1998).
- Galve-Roperh I, Sánchez C, Cortés ML et al. Anti-tumoural action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med.6, 313–319 (2000).
- Guzman M, Galve-Roperh I, Sanchez C. Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol. Sci.22, 19–22 (2001).
- Carracedo A, Geelen MJ, Diez M, Hanada K, Guzmán M, Velasco G. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochem. J.380, 435–440 (2004).
- Carracedo A, Lorente M, Egia A et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell9, 301–312 (2006).
- Guzmán M, Sánchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol. Ther.95, 175–184 (2002).
- Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol. Life Sci.63, 2057–2066 (2006).
- Gong JP, Onaivi ES, Ishiguro H et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res.1071, 10–23 (2006).
- Stella N. Cannabinoid signaling in glial cells. Glia48, 267–277 (2004).
- Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J.20, 2405–2407 (2006).
- Van Sickle MD, Duncan M, Kingsley PJ et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science310, 329–332 (2005).
- Sánchez C, de Ceballos ML, del Pulgar TG et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res.61, 5784–5789 (2001).
- Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumours. Brain Res.1137, 161–169 (2007).
- Held-Feindt J, Dörner L, Sahan G, Mehdorn HM, Mentlein R. Cannabinoid receptors in human astroglial tumours. J. Neurochem.98, 886–893 (2006).
- Duntsch C, Divi MK, Jones T et al. Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. J. Neurooncol.77, 143–152 (2006).
- Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev.54, 161–202 (2002).
- Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumour effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J. Pharmacol. Exp. Ther.308, 838–845 (2004).
- Recht LD, Salmonsen R, Rosetti R et al. Antitumour effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem. Pharmacol.62, 755–763 (2001).
- Pagotto U, Marsicano G, Fezza F et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab.86, 2687–2696 (2001).
- Maccarrone M, Attinà M, Cartoni A, Bari M, Finazzi-Agrò A. Gas chromatography–mass spectrometry analysis of endogenous cannabinoids in healthy and tumoural human brain and human cells in culture. J. Neurochem.76, 594–601 (2001).
- Petersen G, Moesgaard B, Schmid PC et al. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-brain tissue. J. Neurochem.93, 299–309 (2005).
- Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol. Biochem. Behav.81, 224–238 (2005).
- Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem.275, 31938–31945 (2000).
- Jacobsson SO, Wallin T, Fowler CJ. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther.299, 951–959 (2001).
- Maccarrone M, Pauselli R, Di Rienzo M, Finazzi-Agrò A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem. J.366, 137–144 (2002).
- Contassot E, Wilmotte R, Tenan M et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J. Neuropathol. Exp. Neurol.63, 956–963 (2004).
- Riboni L, Campanella R, Bassi R et al. Ceramide levels are inversely associated with malignant progression of human glial tumours. Glia39, 105–113 (2002).
- Ellert-Miklaszewska A, Kaminska B, Konarska L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal.17, 25–37 (2005).
- Sanchez C, Rueda D, Segui B, Galve-Roperh I, Levade T, Guzman M. The CB1 cannabinoid receptor astrocytes is coupled to sphingomyelin hydrolisis through the adaptor protein fan. Mol. Pharmacol.59, 955–959 (2001).
- Diaz-Laviada I, Ruiz-Llorente L. Signal transduction activated by cannabinoid receptors. Mini Rev. Med. Chem.5, 619–630 (2005).
- Day TA, Rakhshan F, Deutsch DG. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol.59, 1369–1375 (2001).
- Manev H, Uz T, Sugaya K, Qu T. Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J.14, 1464–1469 (2000).
- Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science294, 1871–1875 (2001).
- Blázquez C, Casanova ML, Planas A et al. Inhibition of tumour angiogenesis by cannabinoids. FASEB J.17, 529–531 (2003).
- Blazquez C, Gonzales-Feria L, Alvarez L, Haro L, Llanos Casanova M, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res.64, 5617–5623 (2004).
- Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br. J. Pharmacol.144, 1032–1036 (2005).
- Blazquez C, Carracedo A, Salazar M et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology (2007) (Epub ahead of print).
- Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumourigenic, stem-like neural precursors from human glioblastoma. Cancer Res.64, 7011–7021 (2004).
- Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl Acad. Sci. USA101, 781–786 (2004).
- Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumours contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia39, 193–206 (2002).
- Aguado T, Carracedo A, Julien B et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J. Biol. Chem.282, 6854–6862 (2007).
- Herdener M, Heigold S, Saran M, Bauer G. Target cell-derived superoxide anions cause efficiency and selectivity of intercellular induction of apoptosis. Free Radic. Biol. Med.29, 1260–1271 (2000).
- Schimmel M, Bauer G. Proapoptotic and redox state-related signaling of reactive oxygen species generated by transformed fibroblasts. Oncogene21, 5886–5896 (2002).
- Casanova ML, Blázquez C, Martínez-Palacio J et al. Inhibition of skin tumour growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest.111, 43–50 (2003).
- Gallily R, Even-Chena T, Katzavian G, Lehmann D, Dagan A, Mechoulam R. Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk. Lymphoma44, 1767–1773 (2003).
- Cabral GA, Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol.78, 1192–1197 (2005).
- Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem.95, 437–445 (2005).
- Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. Toxicity and carcinogenicity of Δ9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam. Appl. Toxicol.30, 109–117 (1996).
- Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot. Essent. Fatty Acids66, 319–332 (2002).
- Zhu LX, Sharma S, Stolina M et al. Δ-9-tetrahydrocannabinol inhibits antitumour immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol.165, 373–380 (2000).
- McKallip RJ, Nagarkatti M, Nagarkatti PS. Δ-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumour immune response. J. Immunol.174, 3281–3289 (2005).
- Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumour necrosis factor α-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res.64, 1943–1950 (2004).
- Guzmán M, Duarte MJ, Blázquez C et al. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer95, 197–203 (2006).
- Dinnes J, Cave C, Huang S, Milne R. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer86, 501–505 (2002).
- Nagasubramanian R, Dolan ME. Temozolomide: realizing the promise and potential. Curr. Opin. Oncol.15, 412–418 (2003).